From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

The return of Chelsea forward Catarina Macario highlights the 23-player United States women's national team roster selected ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Pope Francis issued a major rebuke Tuesday to the Trump administration’s plans for mass deportations of migrants , warning ...